RNXT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.849

Open

0.803

VWAP

0.81

Vol

80.69K

Mkt Cap

29.14M

Low

0.792

Amount

65.53K

EV/EBITDA(TTM)

--

Total Shares

36.65M

EV

19.10M

EV/OCF(TTM)

--

P/S(TTM)

--

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Show More

Events Timeline

(ET)

2026-02-27

08:50:00

RenovoRx Announces 12 Cancer Centers Using RenovoCath

2026-02-26 (ET)

2026-02-26

08:40:00

RenovoRx Clinical Data Abstract Accepted

2026-02-10 (ET)

2026-02-10

08:50:00

RenovoRx Forms Medical Advisory Board to Support RenovoCath

2026-02-05 (ET)

2026-02-05

08:40:00

RenovoRx Appoints Mark Voll as CFO

2026-02-04 (ET)

2026-02-04

08:40:00

RenovoRx to Present New Clinical Data at 2026 SIO Annual Meeting

2026-01-20 (ET)

2026-01-20

08:40:00

RenovoRx Increases Cancer Centers to 9

2026-01-08 (ET)

2026-01-08

09:00:00

RenovoRx Presents TIGeR-PaC Clinical Trial Data at Oncology Symposium

2025-11-13 (ET)

2025-11-13

16:42:39

RenovoRx announces Q3 earnings per share of 8 cents, matching two forecasts of 8 cents.

News

Yahoo Finance

02-28Yahoo Finance

RenovoRx Expands RenovoCath Adoption Across U.S. Cancer Centers

Newsfilter

02-27Newsfilter

RenovoRx Expands Market for Cancer Treatment Device

Newsfilter

02-26Newsfilter

RenovoRx Clinical Data Abstract Accepted for Presentation at SIR 2026

Benzinga

Wall Street Analysts Adjust Ratings

Newsfilter

02-10Newsfilter

RenovoRx Forms Medical Advisory Board to Enhance Oncology Strategies

Newsfilter

02-04Newsfilter

RenovoRx Announces New Clinical Data Presentation

4 Analyst Rating

Wall Street analysts forecast RNXT stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

5.63

High

12.50

Current: 0.000

Low

3.00

Averages

5.63

High

12.50

JonesResearch

Justin Walsh

initiated

$8

AI Analysis

2026-01-29

Reason

JonesResearch

Justin Walsh

Price Target

$8

AI Analysis

2026-01-29

initiated

Reason

JonesResearch analyst Justin Walsh initiated coverage of RenovoRx with a Buy rating and $8 price target. RenovoRx is a commercial stage medical technology company with an FDA-cleared dual-balloon catheter, RenovoCath, designed to improve delivery of anti-cancer drugs to tumors with poor blood supply, the analyst tells investors in a research note. The firm sees the device being "particularly useful" for treating pancreatic cancer.

Alliance Global

Buy

maintain

$3

2025-11-14

Reason

Alliance Global

Price Target

$3

2025-11-14

maintain

Buy

Reason

Alliance Global lowered the firm's price target on RenovoRx to $3 from $3.50 and keeps a Buy rating on the shares after the company reported Q3 earnings that were within expectations. The firm cites lower forecasts and modestly higher expected dilution for its reduced target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RNXT

Unlock Now

Valuation Metrics

The current forward P/E ratio for RenovoRx Inc (RNXT.O) is -2.18, compared to its 5-year average forward P/E of -3.00. For a more detailed relative valuation and DCF analysis to assess RenovoRx Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.00

Current PE

-2.18

Overvalued PE

-1.36

Undervalued PE

-4.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

4.12

Current PS

12.74

Overvalued PS

13.59

Undervalued PS

-5.35

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

list of strong buy stocks under $3.00

Intellectia · 94 candidates

Price: <= $3.00Analyst Consensus: Strong Buy

Ticker

Name

Market Cap$

Akari Therapeutics PLC

9.32M

Plus Therapeutics Inc

52.05M

Reviva Pharmaceuticals Holdings Inc

38.21M

Intensity Therapeutics Inc

23.85M

Mereo BioPharma Group PLC

84.34M

Atossa Therapeutics Inc

77.93M

Whales Holding RNXT

Trading Trends

People Also Watch

Frequently Asked Questions

What is RenovoRx Inc (RNXT) stock price today?

The current price of RNXT is 0.7951 USD — it has decreased -3.05

What is RenovoRx Inc (RNXT)'s business?

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

What is the price predicton of RNXT Stock?

Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is5.63 USD with a low forecast of 3.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is RenovoRx Inc (RNXT)'s revenue for the last quarter?

RenovoRx Inc revenue for the last quarter amounts to 266.00K USD, decreased

What is RenovoRx Inc (RNXT)'s earnings per share (EPS) for the last quarter?

RenovoRx Inc. EPS for the last quarter amounts to -0.08 USD, decreased -20.00

How many employees does RenovoRx Inc (RNXT). have?

RenovoRx Inc (RNXT) has 10 emplpoyees as of March 12 2026.

What is RenovoRx Inc (RNXT) market cap?

Today RNXT has the market capitalization of 29.14M USD.